ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 34 of 333 for:    "Eye Diseases, Hereditary" OR "Lenz microphthalmia syndrome"

DMEK Versus DSAEK Study (DMEK)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02793310
Recruitment Status : Recruiting
First Posted : June 8, 2016
Last Update Posted : August 30, 2017
Sponsor:
Collaborator:
ZonMw: The Netherlands Organisation for Health Research and Development
Information provided by (Responsible Party):
Maastricht University Medical Center

Brief Summary:
The purpose of this study is to determine whether corneal transplantation by Descemet Membrane Endothelial Keratoplasty more favourable and cost-effective is compared to Descemet Stripping Automated Endothelial Keratoplasty for Fuchs Endothelium Corneal Dystrophy.

Condition or disease Intervention/treatment Phase
Fuchs' Endothelial Dystrophy Procedure: DMEK Procedure: DSAEK Not Applicable

Detailed Description:

FECD is a progressive, multifactorial and irreversible disease characterized by accelerated loss of corneal endothelial cells in the innermost layer of the cornea that leads to vision impairment and potential blindness if left untreated. FECD is responsible for more than 50% of the 1.300 annual corneal transplantations in the Netherlands.

Corneal transplantation improves vision and quality of life in patients with corneal disease. Currently, the standard of care for patients with Fuchs Endothelial Corneal Dystrophy (FECD) is Descemet Stripping Automated Endothelial Keratoplasty (DSAEK), in which only the posterior layers of the cornea are transplanted. However, visual recovery following DSAEK is suboptimal. Descemet Membrane Endothelial Keratoplasty (DMEK), the latest technique in corneal transplantation involves transplantation of only a monolayer of corneal endothelium and Descemet's membrane providing the thinnest endothelial graft possible. DMEK has been suggested to result in faster and better visual recovery compared to DSAEK. While the economic burden, both medical and social, from this disease has not been assessed to date, costs associated with corneal transplantation reach $ 110 million dollars yearly for the 47.000 transplantations in the USA.

The objective of this project is to assess the effects and costs of DMEK vs. DSAEK in order to determine whether the new technique is effective and cost-effective over the standard technique.

The primary outcome measure is best-corrected visual acuity. Secondary outcome measures are contrast acuity, astigmatism, quality of vision, endothelial cell loss, incidence of graft rejection, primary graft failure, cornea donor loss due to preparation, and generic and vision-related quality of life.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 56 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: Corneal Transplantation by DMEK - is it Really Better Than DSAEK?
Actual Study Start Date : October 2016
Estimated Primary Completion Date : November 2018
Estimated Study Completion Date : April 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: DMEK
The intervention group will receive cornea transplantation by DMEK
Procedure: DMEK
The intervention group will receive cornea transplantation by DMEK

Active Comparator: DSAEK
The usual care / control group will receive cornea transplantation by DSAEK
Procedure: DSAEK
The usual care / control group will receive cornea transplantation by DSAEK




Primary Outcome Measures :
  1. Change in best-corrected visual acuity [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Visual acuity will be measured by ETDRS letter charts


Secondary Outcome Measures :
  1. Change in contrast sensitivity [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Contrast sensitivity will be measured using the CSV-1000 chart by Vector Vision

  2. Change in astigmatism [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Astigmatism will be measured using the The Pentacam HR (Oculus Inc., Lynnwood, USA)

  3. Change in corneal scatter [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Corneal scatter will be measured using a confocal microscope

  4. Change in endothelial cell loss [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Endothelial cell loss will be measured using specular microscopy photography.

  5. Incidence of graft rejection [ Time Frame: 3, 6, 12 months post-operatively ]
  6. Incidence of primary graft failure [ Time Frame: 3, 6, 12 months post-operatively ]
    Primary Graft failure will be assessed during ophthalmic examination.

  7. Incidence of cornea donor loss due to preparation [ Time Frame: Preoperatively ]
    The eye bank providing the donor cornea's will register cornea donor loss if a complication occurs during preparation that renders the cornea unusable.

  8. Change in generic quality of life [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Generic quality of life will be measured using the HUI3 (Health Utility Index Mark 3), which test 8 dimensions: vision, hearing, speech, ambulation, dexterity, emotion, cognition and pain.

  9. Change in generic quality of life [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Generic quality of life will be measured using the EQ-5D-5L questionnaire, which tests 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.

  10. Change in vision-related quality of life [ Time Frame: Preoperatively and 3, 6, 12 months post-operatively ]
    Vision-related quality of life will be measured using the National Eye Institute Visual Function Questionnaire (NEI VFQ-25), which is specified for vision-related quality of life.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Cornea decompensation caused Fuchs Endothelial Corneal Dystrophy

Exclusion Criteria:

  • Ocular comorbidities other than cataract
  • Previous corneal transplantation
  • Human leukocyte antigen (HLA) matched keratoplasty
  • Inability to complete follow-up

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02793310


Contacts
Contact: Suryan Dunker, MSc 4383877131 ext 0031 suryan.dunker@mumc.nl
Contact: Frank van den Biggelaar, PhD 433877344 ext 0031 f.vandenbiggelaar@mumc.nl

Locations
Netherlands
Maastricht University Medical Centre Recruiting
Maastricht, Limburg, Netherlands, 6202 AZ
Contact: Frank van den Biggelaar, PhD    0031433877377    f.vanden.biggelaar@mumc.nl   
Sponsors and Collaborators
Maastricht University Medical Center
ZonMw: The Netherlands Organisation for Health Research and Development
Investigators
Principal Investigator: Rudy Nuijts, PhD Department of Ophthalmology, Maastricht University Medical Centre

Additional Information:
Publications:
Responsible Party: Maastricht University Medical Center
ClinicalTrials.gov Identifier: NCT02793310     History of Changes
Other Study ID Numbers: NL55972.068.15
First Posted: June 8, 2016    Key Record Dates
Last Update Posted: August 30, 2017
Last Verified: August 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Additional relevant MeSH terms:
Fuchs' Endothelial Dystrophy
Corneal Dystrophies, Hereditary
Corneal Diseases
Eye Diseases
Eye Diseases, Hereditary
Genetic Diseases, Inborn